Patents by Inventor Soo-Il Chung
Soo-Il Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7722887Abstract: The present invention relates to detoxified and immunologically active proteins (“mutant LTs”) having mutated amino acid sequences of heat-labile enterotoxin of E. coli, DNA sequences encoding the mutant LTs, recombinant expression vectors comprising the DNAs, recombinant microorganisms transformed with the recombinant expression vectors, process for preparing the mutant LTs and pharmaceutical application of the said protein as immunogenic antigens for vaccination and as adjuvants for anti-body production. In contrast to wild-type LT, the mutant LTs did not induce any toxic activities. The mutant LTs elicited high and comparable levels of anti-LT antibodies when delivered either intragastrically or intranasally, inducing systemic and local responses in serum and fecal extracts. Thus, they might be useful for the development of a novel diarrheal vaccine in humans and animals.Type: GrantFiled: September 15, 1999Date of Patent: May 25, 2010Assignee: Mogam Biotechnology Research InstituteInventors: Eun Jeong Park, Jang Seong Kim, Jihoon Chang, Jungsun Yum, Soo-il Chung
-
Patent number: 7485619Abstract: The present application discloses a therapeutic antimicrobial composition comprising mucocidin antimicrobial peptides or analogue or fragments thereof having antimicrobial activity.Type: GrantFiled: January 31, 2006Date of Patent: February 3, 2009Inventors: Yeon Sook Kim, Suk Keun Lee, Soo Il Chung, Sang Chul Park
-
Patent number: 7422874Abstract: The present invention relates to an expression vector for animal cells. Specifically, the present invention relates to an expression vector, pMS vector, pSG vector and pMSG vector, including the human ?-globin 5? MAR complementary sequence or/and the transcription termination site of the gastrin gene. An expression system using an expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.Type: GrantFiled: July 27, 2001Date of Patent: September 9, 2008Assignees: Mogam Biotechnology Research Institute, Neurotech Pharmaceuticals Co., Ltd.Inventors: Jong-Mook Kim, Jung-Seob Kim, Sun-Mo Oh, Jae-Seung Yoon, Kwang-Hee Baek, Soo-Il Chung, Doo-Hong Park, Yeup Yoon
-
Patent number: 7118905Abstract: The present invention provides a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical with the human apolipoprotein (a) kringle domains IV36, IV37 and V38, a cDNA sequence encoding the LK68, a recombinant expression vector comprising the cDNA, a recombinant microorganism transformed with the recombinant expression vector and a novel use of the LK68 as an anticancer agent and a method for treating angiogenesis-mediated disease. LK68, LK6, LK7 and LK8 exhibit inhibitory activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration. LK68 and its single kringles also inhibit the normal development of capillaries in the chick embryo chorioallantoic membrane (CAM). It was also showed that systemic administration of LK68 causes the inhibition of primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis.Type: GrantFiled: May 19, 2004Date of Patent: October 10, 2006Assignee: Mogam Biotechnology Research InstituteInventors: Jihoon Chang, Jang Seong Kim, Eun Jeong Park, Jung-sun Yum, Soo-il Chung
-
Publication number: 20060172940Abstract: The present application discloses a therapeutic antimicrobial composition comprising mucocidin antimicrobial peptides or analogue or fragments thereof having antimicrobial activity.Type: ApplicationFiled: January 31, 2006Publication date: August 3, 2006Applicant: CORAM BIOSCIENCE, INC.Inventors: Yeon Sook KIM, Suk Keun LEE, Soo Il CHUNG
-
Publication number: 20040259202Abstract: The present invention provides a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical with the human apolipoprotein (a) kringle domains IV36, IV37 and V38, a cDNA sequence encoding the LK68, a recombinant expression vector comprising the cDNA, a recombinant microorganism transformed with the recombinant expression vector and a novel use of the LK68 as an anticancer agent and a method for treating angiogenesis-mediated disease. LK68, LK6, LK7 and LK8 exhibit inhibitory activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration. LK68 and its single kringles also inhibit the normal development of capillaries in the chick embryo chorioallantoic membrane (CAM). It was also showed that systemic administration of LK68 causes the inhibition of primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis.Type: ApplicationFiled: May 19, 2004Publication date: December 23, 2004Inventors: Jihoon Chang, Jang Seong Kim, Eun Jeong Park, Jung-sun Yum, Soo-il Chung
-
Patent number: 6743428Abstract: The present invention provides a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical with the human apolipoprotein (a) kringle domains IV36, IV37 and V38, a cDNA sequence encoding the LK68, a recombinant expression vector comprising the cDNA, a recombinant microorganism transformed with the recombinant expression vector and a novel use of the LK68 as an anticancer agent and a method for treating angiogenesis-mediated disease. LK68, LK6, LK7 and LK8 exhibit inhibitory activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration. LK68 and its single kringles also inhibit the normal development of capillaries in the chick embryo chorioallantoic membrane (CAM). It was also showed that systemic administration of LK68 causes the inhibition of primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis.Type: GrantFiled: March 15, 2002Date of Patent: June 1, 2004Assignee: Mogam Biotechnology Research InstituteInventors: Jihoon Chang, Jang Seong Kim, Eun Jeong Park, Jung-sun Yum, Soo-Il Chung
-
Publication number: 20040038394Abstract: The present invention relates to a expression vector for animal cells. Specifically, the present invention relates to a expression vector, pMS vector, pSG vector and pMSG, vector, including the human &bgr;-globin 5′ MAR complementary sequence or/and the transcription termination site of gastrin gene. An expression system using the expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.Type: ApplicationFiled: August 4, 2003Publication date: February 26, 2004Inventors: Jong-Mook Kim, Jung-Seob Kim, Sun-Mo Oh, Jae-Seung Yoon, Kwang-Hee Baek, Soo-Il Chung, Doo-Hong Park, Yeup Yoon
-
Patent number: 6692735Abstract: The present invention relates to a variant of Lkn-1(shLkn-1) with enhanced biological activity, which is a truncated form of Lkn-1, a process for preparing a recombinant shLkn-1 by employing expression vector therefor and pharmaceutical application of the said protein. shLkn-1 is generated by missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Recombinant shLkn-1 inhibits colony formation and cell proliferation in vivo, which suggests that it can be used as a potential drug for the antibody production, the treatment during HIV-1 infection, the protection of bone marrow stem cells during chemotherapy or radiotherapy, and the inhibition of leukemia.Type: GrantFiled: July 21, 1999Date of Patent: February 17, 2004Assignees: Korea Green Cross Corporation, Mogam Biotechnology Research InstituteInventors: Byoung S. Kwon, Byung S. Youn, Soo-Il Chung, Doo-Hong Park, Seung Jae Baek, Eun-Kyoung Lee, Ju-Hyung Ahn, Kong-Ju Lee
-
Patent number: 6500647Abstract: The present invention relates to a recombinant expression vector which is prepared by inserting a human parathyroid hormone gene containing a urokinase-specific cleavage site into an L-arabinose inducible vector containing a phosphoribulokinase gene fragment of Rhodabacter sphaeroides or its mutated gene as a fusion partner, or its mutate gene as a fusion partner, a recombinant microorganism transformed with the said expression vector, and a process for preparing human parathyroid hormone on a large scale by cultivating the said microorganism in a medium containing L-arabinose. In accordance with the invention, a recombinant human PTH having the same activity of the native human PTH can be prepared in a high yield through the precise control of induction by a manufacturing process which comprises a step of inducing expression of fusion protein in the microorganism transformed with the recombinant expression vector by L-arabinose.Type: GrantFiled: January 20, 2000Date of Patent: December 31, 2002Assignee: Mogam Biotechnology Research InstituteInventors: Eun-Kyung Jung, Doo-Hong Park, Soo-Il Chung
-
Patent number: 6365727Abstract: The present invention relates to gene and peptide sequences of a diabetes-specific endogenous retrovirus which is derived from type 1 diabetes patients. In particular, the present invention relates to a whole genome of the diabetes-specific variant of endogenous retrovirus (ERV-9) purified from pancreatic tissues of type 1 diabetes (insulin-dependent diabetes mellitus [IDDM]) patients and its genes and peptide and their sequences, which can be used as a diagnosing reagent for type 1 diabetes and as an immunogen. The diabetes-specific retrovirus expressed exclusively in pancreatic beta cells was purified from deceased type 1 diabetes patients. Subsequently, the retroviral gene sequences were determined, and by analyzing the amino acid sequence of the peptide deduced from the gene, 21 domains of the peptide having hydrophilicity and immuno-dominancy were identified.Type: GrantFiled: July 22, 1998Date of Patent: April 2, 2002Assignee: Green Cross Vaccine CorporationInventors: Ji-Won Yoon, Hee-Sook Jun, Hae-Joon Park, Jong Seong Ahn, Young-Ju Ha, Soo-Il Chung
-
Patent number: 5958752Abstract: The sequences of a pair of human proteins, trichohyalin and transglutaminase-3, in addition to the sequence of the mouse transglutaminase-3 protein, have been discovered. The enzyme transglutaminase-3 is used to cross-link the structural protein trichohyalin in order to form a gel.Type: GrantFiled: February 14, 1997Date of Patent: September 28, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter M. Steinert, Seung-Chul Lee, In-Gyu Kim, Soo-Il Chung, Sang-Chul Park
-
Patent number: 5616500Abstract: The sequences of a pair of human proteins, trichohyalin and transglutaminase-3, in addition to the sequence of the mouse transglutaminase-3 protein, have been discovered. The enzyme transglutaminase-3 is used to cross-link the structural protein trichohyalin in order to form a gel.Type: GrantFiled: April 30, 1993Date of Patent: April 1, 1997Assignee: The United States of America as represented by the Department of Health & Human ServicesInventors: Peter M. Steinert, In-Gyu Kim, Soo-Il Chung, Sang-chul Park